Cambiotics Enrolls First Patient in 70-Firefighter PFAS Probiotic Trial
Copenhagen – November 03, 2026 -- Cambiotics ApS has enrolled the first participant in its first human clinical trial, testing whether its probiotic strain 46-SL1 changes serum PFAS concentrations in 70 firefighters with prior occupational exposure.
Crossover trial runs 2 x 12 weeks in Chicago
The study is randomised, double-blind and placebo-controlled. Atlantia Clinical Trials is conducting it in Chicago, Illinois (NCT07846371). Researchers are also assessing safety, tolerability and fecal microbiome changes. 46-SL1 is being developed as a dietary supplement.
Dr. Stacey Boetto of Atlantia Clinical Trials is the Principal Investigator.